FULCRUM THERAPEUTICS, INC. Payments of Stock Issuance Costs
FULCRUM THERAPEUTICS, INC. (FULC) reported Payments of Stock Issuance Costs of $333.00 thousand for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $333.00K.
- FULCRUM THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-03-31 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 6 month as first filed | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $333.00K S-4 · filed 2026-09-02 | ||
| 2026-03-31 | $333.00K 10-Q · filed 2026-04-27 | |||
| 2025-06-30 | $0.00 derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $0.00 S-4 · filed 2026-09-02 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-04-27 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $34.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $34.00K 10-Q · filed 2020-08-11 | $739.00K 10-Q · filed 2019-08-26 | |
| 2019-03-31 | $34.00K 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |